SR9243 is a selective modulator of the orphan nuclear receptor RORγt, primarily investigated for its role in modulating immune responses. It has shown promise in preclinical studies for treating autoimmune diseases by suppressing the differentiation and function of Th17 cells, which are implicated in conditions such as multiple sclerosis, psoriasis, and inflammatory bowel disease. By inhibiting RORγt, SR9243 reduces the production of pro-inflammatory cytokines like IL-17, thereby dampening pathological inflammation. Additionally, SR9243 has been explored in cancer immunotherapy due to its ability to alter the tumor microenvironment, potentially enhancing anti-tumor immune responses. Its application remains largely in the research phase, with focus on optimizing efficacy and safety for therapeutic use.